Management of Low Pulmonary Vital Capacity Secondary to Bone Cancer
Evaluation and Diagnosis
- The American College of Radiology recommends a complete imaging evaluation, including standard radiographs followed by a thoracic scan to assess the extent of pulmonary and bone involvement 1
- The National Comprehensive Cancer Network suggests that MRI is indicated in cases of suspected neurological complications, particularly spinal cord compression 2, 1
- A comprehensive evaluation should include a bone scintigraphy, chest radiography, and a thoraco-abdomino-pelvic scan with contrast to determine the extent of the disease 1
Therapeutic Approach
Treatment of Pulmonary Function
- The European Society for Medical Oncology recommends oxygen therapy for patients with significant hypoxemia 3
Treatment of Bone Cancer
- The National Comprehensive Cancer Network recommends that treatment be determined by a multidisciplinary team specializing in the management of bone tumors, including oncologists, radiotherapists, surgeons, radiologists, and palliative care specialists 4, 2
- For metastatic bone lesions causing respiratory symptoms:
- External beam radiation therapy is effective with response rates of 70-80% for pain relief and tumor mass reduction 3
- A single fraction of radiation therapy is recommended for uncomplicated bone metastases, offering convenience and similar efficacy to fractionated treatments 3
- Stereotactic body radiation therapy (SBRT) may be considered for vertebral lesions, with a risk of vertebral fracture of 10-20% 5
- For thoracic vertebral metastases causing compression:
- A dose of dexamethasone of 16-24 mg/day should be administered promptly in cases of spinal cord compression 3
- Kyphoplasty is strongly recommended for patients with painful vertebral fractures, offering immediate pain relief and functional improvement 6
- Surgery followed by radiation therapy is indicated for patients with good general condition and localized spinal cord compression 3
Systemic Treatment
- The European Society for Medical Oncology recommends agents targeting the bone (bisphosphonates and denosumab) to prevent skeletal events and reduce morbidity 3, 5
- Chemotherapy depends on the type of bone cancer:
- For osteosarcoma: cisplatin and doxorubicin, or MAP (high-dose methotrexate, cisplatin, and doxorubicin) 4, 7
- For Ewing's sarcoma: VAC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide) 7, 1
- For conventional chondrosarcoma: primarily surgical as it is chemoresistant 1
Follow-up and Surveillance
- Patients should be followed up every 3 months for 2 years, then every 6 months until 5 years, and every 8-12 months until 10 years 8, 1
- Follow-up should include regular thoracic imaging examinations and an evaluation of pulmonary function 8, 1
- Long-term surveillance of the toxic effects of chemotherapy, surgery, and radiation therapy should continue for more than 10 years after treatment 1
Important Points and Pitfalls to Avoid
- Delayed referral to specialized centers can have a negative impact on outcomes 1
- Particular attention should be paid when conventional or SBRT radiation therapy is performed in conjunction with systemic treatment, due to their potential radiosensitizing effect 5
- Secondary cancers can occur in survivors of bone sarcomas, related or not to irradiation 1
- Long-term cardiac evaluation is important as cardiac function deterioration can occur decades after treatment with anthracyclines 1
- The presence of severe pain alone is a sufficient indication for kyphoplasty in patients with metastatic disease 6